Therapies / Neurology / Research / Therapeutics / Brain / Drugs / Drug / Gene / Genes / Gene Therapy / Genetics / Boston blog main / Boston top stories / National blog main / National top stories / New York / New York blog main / New York top stories / San Francisco blog main / San Francisco top stories / Acadia Pharmaceuticals / Acorda Therapeutics / Adamas Pharmaceuticals / Alector / Alexion Pharmaceuticals / Asa Abeliovich / Columbia University / deals / dyskinesia / FDA / GBA1 / Jonathan Silverstein / Leonard Bell / Levodopa / Life Sciences / Lysosomal Therapeutics / Michael J. Fox Foundation / National Parkinson Foundation / Neurodegenerative Diseases / OrbiMed Advisors / Parkinson’s Institute and Clinical Center / pimavanserin / Prevail Therapeutics / RegenxBio / Silverstein Foundation / startups / Steve Squinto / VC / Voyager Therapeutics

For Parkinson's, Two Drugs Coming And One New Co as Prevail Starts in NY

Posted on: Aug 9, 2017   |   Posted by: Biotech Mag

For Parkinson's, Two Drugs Coming And One New Co as Prevail Starts in NY

A drug that actually slows or reverses the brain damage inflicted by Parkinson's disease, rather than just alleviates its often debilitating symptoms, remains elusive. But...

Continue reading ...